Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Director/PDMR Shareholding

7 Aug 2020 07:00

RNS Number : 4314V
Feedback PLC
07 August 2020
 

Feedback plc

 

Grant of Director Options

 

 

London, 07 August 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that it has granted options over 13,498,748 new Ordinary Shares ("CEO Options"), representing 1.27 per cent. of the Company's issued share capital, to Tom Oakley, CEO of Feedback.

 

The CEO Options are exercisable at a price of 1.2 pence at any time up to the tenth anniversary of the date of grant. One-third of the CEO Options vest immediately, one-third will vest one year from date of grant and the balance will vest two years from the date of the grant. The grant of the CEO Options and the issue price were approved by shareholders at the General Meeting of the Company held on 29 August 2019. Of the CEO Options, 12,356,667 were granted pursuant to the EMI Option Scheme and the balance of 1,142,081 options were granted pursuant to the Non Tax-Advantaged Option Scheme.

 

Tom Oakley now hold options over 22,820,829 Ordinary Shares, equivalent to 2.14 % of the Company's voting rights. In total 60,330,829 Options are now outstanding, representing approximately 5.65 % of the Company's current issued share capital.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Tom Oakley

 

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

 

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Feedback plc

b)

 

LEI

 

213800UGOF2GT2U2RV90

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Options over Ordinary Shares of 0.25p each in Feedback plc

 

 

Identification code (ISIN) for Feedback plc ordinary shares: GB0003340550

b)

 

Nature of the transaction

 

Grant of options

c)

 

Price(s) and volume(s)

 

 

Price(s)

Exercise price of

1.2p per share

Volume(s)

 

13,498,748

d)

 

Aggregated information

- Aggregated volume

- Price

- Principal amount

 

 

N/A

 

e)

 

Dates of the transaction

 

6 August 2020

f)

Place of transaction

Outside of a trading venue

 

 

-Ends-

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656

Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880

Instinctif Partners

Melanie Toyne-Sewell / Phillip Marriage

+44 (0)20 7457 2020

+44 7890 022 814

feedbackplc@instinctif.com

 

Notes to editors

 

About Bleepa

 

Bleepa provides instant and remote access to clinical grade medical images through a zero footprint application. The majority of patient cases require medical imaging which can be seamlessly shared to the entire clinical team through Bleepa. Cases can be discussed through its secure instant messaging and image annotation, allowing comments and treatment decisions to be communicated instantly between team members. Bleepa can be accessed from any internet connected device including phones, tablets, laptops and desktops; clinicians can use their own devices and therefore no additional hardware is required.

 

About Feedback plc - www.fbk.com

 

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer.

 

Feedback has launched Bleepa®, a new secure, encrypted medical communication app for clinicians accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS). For more information on Bleepa, see www.bleepa.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHUPURWRUPUGBQ
Date   Source Headline
22nd Apr 20262:10 pmRNSGrant of Options and PDMR dealing
20th Apr 20267:00 amRNSNHS Progress and Business Update
17th Feb 202610:43 amRNSCorrection: Half-year Report
17th Feb 20267:00 amRNSHalf-year Report
2nd Feb 20267:00 amRNSNotice of Results & Retail Investor Presentation
5th Jan 20264:13 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
18th Dec 20257:00 amRNSTrading Update
20th Oct 20257:00 amRNSDirectorate Change
13th Oct 20254:04 pmRNSResult of AGM
18th Sep 20251:07 pmRNSNotice of AGM
17th Sep 20257:00 amRNSFinal Results
8th Sep 20257:00 amRNSNotice of Results & Retail Investor Presentation
10th Jul 20257:00 amRNSGrant of Options and PDMR dealing
12th Jun 20257:00 amRNS-RNeighbourhood Health Service Simulation
7th May 202510:44 amRNSHolding(s) in Company
6th May 20251:01 pmRNSHolding(s) in Company
28th Apr 20257:00 amRNSTrading Update
25th Feb 20257:00 amRNSHalf-year Report
11th Feb 20257:00 amRNSNotice of Results & Investor Presentation
14th Jan 20257:00 amRNSSurrender and grant of options and PDMR dealings
18th Dec 20243:07 pmRNSHolding(s) in Company
18th Dec 20247:00 amRNSHalf Year Trading Update
9th Dec 202410:56 amRNSHolding(s) in Company
9th Dec 202410:48 amRNSHolding(s) in Company
4th Dec 20247:00 amRNSHolding(s) in Company
3rd Dec 202412:33 pmRNSHolding(s) in Company
3rd Dec 202412:18 pmRNSHolding(s) in Company
2nd Dec 202411:53 amRNSHolding(s) in Company
2nd Dec 202411:46 amRNSHolding(s) in Company
2nd Dec 20247:00 amRNSDirector/PDMR Shareholding
29th Nov 20243:36 pmRNSHolding(s) in Company
29th Nov 20243:33 pmRNSHolding(s) in Company
28th Nov 20242:35 pmRNSResult of AGM & Commercial Update
6th Nov 20247:00 amRNSResult of WRAP Retail Offer
4th Nov 20243:46 pmRNSSuccessful Fundraising upscaled to c. £5.57m
4th Nov 20247:02 amRNSWRAP Retail Offer for up to £1 million
4th Nov 20247:01 amRNSProposed Fundraise & Share Capital Reorganisation
4th Nov 20247:00 amRNSFinal Results
16th Oct 20247:00 amRNSElective Recovery Fund funding mechanism
19th Sep 20247:00 amRNSCollaboration Agreement
2nd Sep 20247:00 amRNSFurther funding to extend NHS Trust pathways
10th Jul 20247:00 amRNSVertex In Healthcare Collaboration
1st Jul 20247:00 amRNSCDC Contract Awarded by Queen Victoria Hospital
28th Jun 20247:00 amRNSChange of Name of Nominated Adviser and Broker
22nd May 20247:00 amRNSTrading Update
25th Mar 20247:00 amRNSNew tuberculosis partnership in India

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.